drugset / Trial / NCT01962376
Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators assessed whether the addition of a preoperative regimen of Bevacizumab regimen to improves R0 resection rate and survival among patients with potentially resectable gastric cancer with liver metastasis.
Timeline
- Start
- 2013-02
- Primary completion
- 2014-12
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Background | Capecitabine | Small molecule | 2000 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |